1.Progress in Diagnosis and Treatment of Hereditary Diffuse Gastric Cancer
Chinese Journal of Gastroenterology 2017;22(4):199-202
Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant inherited disease,and may be related to the mutation of CDH1 or CTNNA1 genes.Microscopically,signet-ring cell carcinoma is suggested frequently in endoscopic biopsy or gastrectomy specimens.Some patients may have concomitant extra-stomach tumor (frequently breast cancer in females).Detection of CDH1 gene mutation should be performed in high-risk individuals,and diagnosis and treatment should be carried out by a multidisciplinary team.Prophylactic gastrectomy is recommended for those with pathogenic CDH1 mutation.Endoscopic surveillance is an option for those with CDH1 mutation of undetermined significance and those without germline CDH1 mutation.This review discussed the concept,genetic characteristics,clinicopathological features and genetic screening of HDGC for providing a reference for clinicians.
2.Discussion on quality training and medical education measures for further study physicians in department of vascular surgery
Chinese Journal of Medical Education Research 2012;11(7):735-737
The decade practical training experiences in vascular department of Xuanwu Hospital were reviewed.Quality training and medical education measures for further study physicians in department of vascular surgery were introduced and summarized from medical ethics education,professional training,theoretical knowledge training and quantitative assessment.All these measures were intended to improve the overall quality of vascular surgical further study physicians and to guarantee the most gain for trainees.
3.Protective Effects of Neurotrophin-3 on The Excitotoxic Damage of Cochlear Afferent Neurons in Guinea Pigs
Yongquan ZHANG ; Ming JIANG ; Hong SUN
Journal of Audiology and Speech Pathology 2004;0(05):-
0.05). Conclusion 1. Exogenous glutamate application via scala tympani can result in a rapid excitotoxic damage of cochlear typeⅠspiral ganglion cells of guinea pigs. 2. NT-3 can protect typeⅠspiral ganglion cell from glutamate neurotoxicity even applied 60 minutes after the occurrence of glutamate induced cochlear impairment. The result indicates that NT-3 may be an ideal candidate for the treatment of a series of acute neural hearing loss.It may lead to a better outcome when NT-3 gene therapy is actilized.
4.Implantation of self-expanding stents for treating lower extremity ischemia
Yongquan GU ; Jian ZHANG ; Lixing QI
Chinese Journal of Minimally Invasive Surgery 2005;0(11):-
Objective To explore effects of arterial self-expanding stents implanted in different position for treating lower limb ischemia.Methods Follow-up records of 65 patients of lower limb ischemia(71 limbs) teated by stent implantation from January 2002 to March 2006 were retrospectively reviewed.Out of the 71 patients,there were 38 patients(52.3%) of diabetic lower limb ischemia and 33 patients(47.7%) of non-diabetic ischemia.Stent implantation included 2 abdominal aortic stents in 2 patients,1 abdominal aortic and 2 iliac stents in 1 patient with the Leriche syndrome,38 iliac stents in 33 patients(35 limbs),12 stents for iliacofemoral lesions in 6 patients(6 limbs),23 femoral stents in 16 patients(19 limbs),10 stents for femoral and prioxiaml popliteal arterial lesions in 5 patients(6 limbs),and 2 stents for distal popliteal arterial lesions in 2 patients(2 limbs).Results The patients were followed for 2~50 months(mean,16.1 months).The patency rate was 100% in 3 patients with abdominal aortic stent implantation or abdominal and aortoiliac stent implantation.Iliac artery occlusion occurred in 4 patients(4 limbs),with the patency rate of iliac arterial stents being 88.6%(31/35).The patency rate of femoral arterial stents was 78.9%(15/19),and that of femoral and prioxiaml popliteal arterial stents was 83.3%(5/6).Stents in distal popliteal artery were occluded in all the 2 patients.Stents remained patent after a mean of 5.6 months postoperatively in 3 patients with 2 femoral stents in 2 limbs and 1 femoropopliteal stent in 1 limb while distal outflow arteries were blocked.Conclusions Stent implantation can be the first choice for aortoiliac stenosis or occlusive arterial diseases.It is also recommendable for stenotic or occlusive femoral and proximal popliteal arterial diseases.It is a proper option for the senile patients or those who can not stand bypass procedures.However,for tibial arterial stenosis or occlusion,it is not a favorable consideration.
5.Primary implantation of self-expanding nitinol stents for atherosclerotic occlusive disease of the superficial femoral artery: Intermediateterm results
Lianrui GUO ; Yongquan GU ; Jian ZHANG
Chinese Journal of Minimally Invasive Surgery 2005;0(07):-
0.15) was 81%(17/21) and the clinical improvement of symptoms was achieved in 95%(20/21) of cases.The 17 cases were followed up for a mean of 15.7 months(range,12~35 months).One patient died of cerebral infarction at 6 months postoperatively.One patient with stent occlusion at 3 months after operation was given an embolectomy(the artery has remained patent for 13 months).Stent occlusion also happened in 2 patients(at 3 and 4 months after operation,respectively),on whom a subsequent infragenicular femoropopliteal bypass was operated,and in 2 other patients(at 8 and 12 months after operation,respectively),on whom a below-knee amputation was operated.At one year postoperatively,the patency rate was 75%(15/20) after primary operation and 80%(16/20) after re-operation.The rate of clinical improvement of symptoms was 75%(15/20).The limb salvage rate in patients with critical limb ischemia was 88%(14/16).Conclusions Primary angioplasty with self-expending nitinol stent implantation is a safe, minimally invasive,and effective method,which can be used as the first choice for femoral arterial occlusive diseases,especially in senile patients who cannot tolerate bypass procedures.
6.Performance Evaluation of Sysmex XS-800i Automated Hematology Analyzer
Yan ZHANG ; Yongquan XIA ; Aijun HUANG
Chinese Medical Equipment Journal 1993;0(06):-
0.05).The results differentiated by Sysmex XS-800i showed excellent correlation with those by handwork.Conclusion The performance of the Sysmex XS-800i automated hematology analyzer is satisfied.
7.DETECTION AND LOCATION OF MELATONIN RECEPTOR IN HUMAN SKIN AND ITS MOLECULAR FEATURE
Yongquan SHI ; Hui ZHANG ; Zhimin LIU
Medical Journal of Chinese People's Liberation Army 1982;0(03):-
In order to detect and localize melatonin receptor and its mRNA expression in the human skin, human skin was obtained from healthy volunteers. Immunohistochemistry and RT-PCR were applied to detect MR in human skin and to identify its subcellular distribution. Electrophoresis of RT-PCR product showed positive band of mt 1 subtype in human skin. The subtype of MR, mt 1was present in the membrane, cytosol and nucleus of skin cells as shown by immunohistochemistry. It is suggested that skin is the target organ of melatonin.
8.Effect of nicotinic acid on hyperphosphatemia in maintenance hemodialysis patients
Jianfang ZHANG ; Yongquan LIU ; Shuhua WANG
Chinese Journal of Postgraduates of Medicine 2013;36(34):7-9
Objective To assess the effect of nicotinic acid on hyperphosphatemia in maintenance hemodialysis (MHD) patients.Methods Twenty-six MHD patients with stable disease condition and hyperphosphatemia that could not be successfully controlled by conventional methods were selected.All patients were treated with oral nicotinic acid for 20 weeks.The changes of serum calcium,high sensitivity Creactive protein (hs-CRP),albumin (ALB),aspartate aminotransferase (AST),alanine aminotransferase (ALT),gamma-glutmyltransferase (GGT),total bilirubin (TBIL),derect bilirubin (DBIL),high density lipoprotein cholesferol (HDL-C),low density lipoprotein cholesferol (LDL-C),triacylglycerol (TG),total cholesterol (TC),intact parathyroid hormone,hemoglobin,platelet count,etc were observed before and after treatment.Results Two patients withdrew from this study because.of pruritus and diarrhea after two weeks of oral nicotinic acid.In 24 cases,compared with that before treatment,the serum phosphate,calcium-phosphorus product was decreased [(1.49 ± 0.19) mmol/L vs.(2.13 ± 0.16) mmol/L,(4.40 ± 0.49)mmol2/L2 vs.(5.45 ± 0.36) mmol2/L2] and HDL-C was increased [(1.45 ± 0.14) mmol/L vs.(1.18 ± 0.15)mmol/L] after treatment,and there was significant difference (P < 0.05).There was no significant difference in the serum calcium,iPTH,LDL-C,TG,TC,ALB,AST,ALT,GGT,TBIL,DBIL,hs-CRP,platelet count,hemoglobin between before and after treatment (P > 0.05).Conclusions Nicotinic acid is effective as all adjuvant measure in control of hyperphosphatemia in patients on MHD and can increase HDL-C.It provides a new approach for the treatment of hyperphosphatemia.
9.One case of acute promyelocytic leukemia with 3'RARα submicroscopic deletion
Yongsheng HAN ; Yongquan XUE ; Jun ZHANG
Journal of Leukemia & Lymphoma 2011;20(1):39-41
Objective To report a rare case of M3r subtype of acute promyelocytic leukemia (APL)with 3'-end of RARα (3'RARα) submicroscopic deletion, and the characters of morphologic, cytogenetic,molecular genetic and molecular biology studies. Methods Chromosomes of bone marrow (BM) cells were prepared with direct method and short-term culture method, and R-banding technique was used for karyotypic analysis. Fluorescence in situ hybridization (FISH) assays were performed on fixed BM cells using the following specific DNA probes: CEP X/Y alpha satellite DNA probe, LSI PML-RARα dual-color dual-fusion and LSI RARα dual-color break apart probes. A quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) was performed to detect the PML-RARα transcript. A multiplex nested RT-PCR was also performed, which may simultaneously detect the fusion genes derived from 29 chromosomal aberrations in acute leukemia including PML-RARα, PLZF-RARα and NPM-RARα fusion transcripts. Results R-banding analysis revealed a karyotype of 45,X,-Y[6]/46,XY[8], FISH using CEP X/Y probe further confirmed Y-chromosome loss. FISH analysis with RARα dual-color break apart probe demonstrated a deletion of the entire 3'-end of one allele of RARα gene. Cytogenetic, FISH and RT-PCR analyses showed no PML-RARα,PLZF-RARα, NPM-RARα, NuMA-RARα and STAT5b-RARα rearrangements. Conclusion A new RARαrearrangement involving 3'RARα submicroscopic deletion in APL without X-RARα fusion has been identified.FISH analysis with RARα dual-color break apart probe is a useful method for characterization of this abnormality, but its molecular consequences remain to be elucidated.
10.Clinical observation of Guilong decoction combined western medicine in the treatment of rheumatoid arthritis with cold-dampness syndrome
Meixia LIU ; Guiqi ZHU ; Deyang LU ; Yongquan ZHANG ; Ling WANG
Chinese Journal of Primary Medicine and Pharmacy 2015;(15):2257-2259
Objective To observe clinical effects of Guilong decoction combined conventional western medi-cine in the treatment of rheumatoid arthritis with cold-dampness syndrome.Methods 106 cases of rheumatoid arthri-tis with cold-dampness syndrome were randomly divided into the treatment group and the control group,with 53 cases in each group.The control group was orally given methotrexate and hydroxychloroquine,while the treatment group was given Guilong decoction based on the treatment of the control group.The clinical effects of the two groups were observed after a treatment course of 3 months.Results In the treatment group,35 cases were markedly effective, which was significantly higher than the control group(P <0.05);12 cases were effective,and there was no statistically significant difference with the control group (P >0.05).The total effective rate of the treatment group was 88.68%, which was significantly higher than the control group (χ2 =4.810,P =0.028).There were no significant differences of the adverse reaction ratio between the two groups(P >0.05).Conclusion Guilong decoction combined with con-ventional western medicine can obviously improve the rheumatoid arthritis disease severities,the curative effect is re-markable.It is worth popularizing in clinical application.